+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the pharmacokinetics, safety, and immune response of two drugs, RPH-030 and Vectibix4, in patients with metastatic colorectal cancer mCRC who have wild-type RAS genes. The study aims to show that these treatments are equivalent in how the body processes them and to compare their safety and immune effects. Additionally, the study will explore how effective these drugs are when used as first-line therapy combined with FOLFIRI chemotherapy. Participants will receive either RPH-030 or Vectibix4 intravenously at 6 mgkg every two weeks along with FOLFIRI chemotherapy, which includes irinotecan, calcium folinate, and fluorouracil. Treatment starts with FOLFIRI for 8 cycles, then continues with a modified de Gramont regimen. The study includes several periods a screening phase, a main period lasting up to 6 months, a continued therapy period up to 1 year where all patients receive RPH-030, and a treatment extension period lasting up to 2 years for patients with stable disease or response. Follow-up visits occur after treatment ends to monitor survival and disease status. Participants will undergo regular tumor assessments approximately every 6 to 8 weeks, hospitalizations for drug administration at specific visits, and blood sampling for pharmacokinetic and safety evaluations. Researchers will monitor drug levels over time, adverse events, immune reactions, and tumor responses. Follow-up includes imaging or phone calls to track overall survival and disease progression. The total study participation can last up to about 2 years with additional follow-up to ensure thorough monitoring of outcomes and safety.

Age: 18Years +All GendersPhase 1
26 locations
W

Actively Recruiting

Bipolar disorder is a serious, long-lasting mood condition affecting both adults and children. This research focuses on studying the effects and safety of cariprazine, a medication approved for adults, in treating depressive episodes linked to bipolar I disorder in children and adolescents aged 10 to 17. The study aims to better understand how this drug impacts the pediatric population, where treatment options are currently limited. Participants will be randomly assigned to one of two groups one receiving cariprazine at flexible doses adjusted by age and weight, and the other receiving a placebo. The treatment lasts six weeks, with dose adjustments at week 3 depending on response. Following treatment, there is a four-week safety follow-up period. Weekly visits at clinics or hospitals will support monitoring and treatment. During the study, participants will undergo medical assessments, blood tests, questionnaires, and side effect checks to evaluate the drugs impact. Researchers will track changes in mood symptoms using scales like the Childrens Depression Rating Scale and monitor safety through vital signs, lab tests, and movement assessments. The total study participation spans around 10 weeks, including treatment and follow-up.

Age: 10Years - 17YearsAll GendersPhase 3
81 locations
O

Actively Recruiting

Researchers are conducting a multicenter observational study in the Russian Federation focusing on patients with aggressive high-volume metastatic hormone-sensitive prostate cancer mHSPC. The study aims to analyze treatment patterns and evaluate homologous recombination repair mutations HRRm using circulating tumor DNA ctDNA. The population includes those with high-aggressive Gleason score 8-10 and high-volume disease, with known tumor HRRm status determined from routine tumor samples. Approximately 230 patients will be enrolled, equally representing HRRm and wild-type HRR HRRwt groups. This study involves no additional procedures beyond routine clinical practice. Data collection includes two visits the baseline visit gathers demographic, clinical, and treatment history from medical records and patient interviews, as well as blood samples for ctDNA and HRRm testing performed centrally. The final visit occurs at disease progression or after about 12 months to collect follow-up data on progression to metastatic castration-resistant prostate cancer mCRPC and further treatments. Follow-up data may be collected by telephone if the patient cannot visit the study site. Participants contribute data through medical record reviews, interviews, and routine blood sampling. Researchers will monitor various outcomes including treatment types and durations, progression timelines, mutation presence in ctDNA, and clinical characteristics like Gleason scores and metastasis sites. Data will be entered into electronic records, with the study lasting about 36 months until enrollment and follow-up are complete.

Age: 18Years +MALE
28 locations
O

Actively Recruiting

Researchers are studying the physical impact of Multiple Sclerosis MS from the patients perspective while providing continued access to the drug ocrelizumab. This extension study evaluates the safety and tolerability of ocrelizumab in patients previously enrolled in certain parent studies who no longer have local access to the treatment. The study is open-label and multicenter, sponsored by Hoffmann-La Roche. Participants will receive ocrelizumab at approved doses of either 600 mg via intravenous infusion or 920 mg via subcutaneous injection, following the schedule from their original parent study. Treatment will continue until the medication becomes locally available, an unacceptable safety concern arises, the participant dies, or withdraws consent. During the study, participants will be monitored for changes in physical function using patient-reported outcome measures over up to five years. Researchers will also track access to ocrelizumab, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. The study will last up to five years, with ongoing safety and tolerability assessments throughout the treatment period.

Age: 18Years +All GendersPhase 3
56 locations
O

Actively Recruiting

Researchers are conducting a national, multicenter, prospective observational study focusing on molecular profiling and first-line treatment approaches for patients with aggressive advanced endometrial cancer stage III-IV in the Russian Federation. The study aims to collect real-world data on the prevalence of specific molecular markers such as POLE mutations, mismatch repair status, p53 abnormalities, HER2, and PD-L1 expression, alongside demographic and clinical characteristics of these patients. The study will include approximately 500 female patients newly diagnosed with aggressive advanced endometrial cancer subtypes who have available biopsy or postoperative archival tumor samples. No additional procedures beyond routine clinical practice will be performed. Molecular testing will be conducted centrally using immunohistochemistry and genetic sequencing techniques on tumor samples. Data collection will occur during two visits the baseline visit to gather demographic, clinical, and treatment information, and a follow-up visit six months later or at disease progression to collect further treatment and progression data. Participants will have their clinical and molecular data entered into electronic records by study physicians. The study will monitor several primary outcomes related to the rates of molecular marker positivity over 24 months and secondary outcomes including chemotherapy use, disease progression, patient demographics, and tumor characteristics over 33 months. The total study duration is expected to be about 27 months or until 500 eligible patients have been enrolled and their data collected, including follow-up.

Age: 18Years +FEMALE
19 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness, safety, how the body processes, and immune response to BCD-236 combined with chemotherapy in women with relapsed or metastatic triple negative breast cancer TNBC who have received previous treatments. This is a Phase 2 study that compares BCD-236 plus chemotherapy versus chemotherapy alone in patients whose cancer has returned or progressed after earlier therapies. Participants will be randomly assigned to one of two groups one receiving BCD-236 by intravenous infusion plus chemotherapy chosen by the investigator, and the other receiving chemotherapy alone. Treatment continues until the cancer worsens, side effects become intolerable, or the study ends. During the study, participants will undergo regular assessments including tumor measurements and health evaluations to monitor response and side effects. The main outcome measured is the overall response rate at 24 weeks, with secondary outcomes including progression-free survival, overall survival, disease control rate, time to response, and duration of response assessed at various times up to 102 weeks. Participants will be monitored closely throughout their treatment and follow-up periods.

Age: 18Years - 74YearsFEMALEPhase 2
47 locations
O

Actively Recruiting

Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.

Age: 18Years +All Genders
40 locations
S

Actively Recruiting

Researchers are conducting a multicenter, double-blind, placebo-controlled, randomized clinical trial to study children aged 3 to 12 years with acute respiratory viral infection ARVI. This trial aims to evaluate the safety and effectiveness of Raphamin in treating ARVI symptoms during the seasonal incidence of the illness. Enrollment starts with children aged 6 to 12 years and may expand to include those aged 3 to 12 years based on interim safety and efficacy results. Participants will be randomly assigned to receive either Raphamin or a placebo. Raphamin is given orally as tablets that dissolve in the mouth, with a specific dosing schedule over five days eight tablets on the first day taken at intervals, then one tablet three times daily on days two through five. The placebo group follows the same dosing regimen using placebo tablets. The treatment period lasts five days, followed by monitoring and follow-up visits. During the study, parents or caregivers will record their childs symptoms and body temperature twice daily in an electronic diary, including any use of fever-reducing medications and changes in health. Children will have several visits with healthcare providers on days 1, 5, and 7, plus a phone visit on day 14 for safety and symptom assessment. Laboratory tests and physical exams will be conducted to monitor progress and safety. The primary outcome is the time until ARVI symptoms resolve within 14 days.

Age: 3Years - 12YearsAll GendersPhase 3
35 locations
C

Actively Recruiting

This research aims to compare different preoperative preparation methods in adults with large, complex, or giant incisional hernias needing surgical repair. The study focuses on patients with loss of abdominal wall domain and reduced abdominal cavity volume, where standard surgery can lead to complications such as high tension closure and respiratory issues. It evaluates how various strategies affect surgical outcomes and recovery. Participants are assigned to one of four groups preoperative botulinum toxin A injections to relax the abdominal muscles, progressive preoperative pneumoperitoneum to increase abdominal cavity size, a combination of both methods, or standard preparation without specific optimization. These approaches are tailored based on the hernias clinical and anatomical features. Throughout the study, researchers will assess the success of midline fascial closure during surgery, the need for additional muscle separation techniques, postoperative complications within 30 days, hospital stay length, hernia recurrence after 12 months, and overall patient recovery. The study will monitor these outcomes to help develop better treatment strategies for complex abdominal wall hernias.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are studying pediatric participants aged 4 weeks to less than 12 years with human immunodeficiency virus type 1 HIV-1 infection, weighing under 45 kg. The study focuses on treatment-naive children or those virologically suppressed on stable combination antiretroviral therapy for at least 3 months without treatment failure. The main goals are to evaluate the steady-state pharmacokinetics, safety, and tolerability of doravirine DOR when given with two nucleosidenucleotide reverse transcriptase inhibitors NRTIs or as part of the fixed-dose combination FDC of DORlamivudinetenofovir disoproxil fumarate DOR3TCTDF in children aged 6 to less than 12 years weighing 14 to less than 45 kg. Participants receive oral doravirine doses ranging from 7.2 mg to 100 mg based on weight, combined with two NRTIs according to local guidelines, or the fixed-dose combination DOR3TCTDF, for a treatment period of 96 weeks. Those completing the Week 96 visit may join an extension study to receive doravirine for up to an additional 224 weeks or until commercial availability. The study is open-label and conducted across multiple sites. During the study, participants undergo intensive pharmacokinetic sampling at designated times up to 24 hours postdose to measure doravirine levels in plasma. Researchers also monitor safety outcomes up to 24 weeks and additional secondary outcomes including viral load, CD4 T-cell counts, adverse events, adherence, and palatability of the oral pellets or granules. Assessments continue through Week 96, with close monitoring of viral suppression, drug resistance, and tolerability throughout the study and extension period.

Age: 4Weeks - 11YearsAll GendersPhase 2
26 locations

1-10 of 25

1